Sector explainers
Biotech cash runway: what the next milestone actually costs
A simple months-of-cash figure can miss one-off costs, repayment dates and the spending needed after a trial result.
For a medicine developer, having cash until a trial result and having enough cash to act on that result are different questions. A useful funding assessment connects the balance sheet to a dated spending plan.
Check the starting point
Begin with the date of the reported cash balance and whether the money is available for general use. Then read cash movements since that date. A later capital raise or repayment can materially change the position.
Use the cash-flow statement alongside the accounts. An accounting loss is not the same as cash spent, and money raised by selling shares is not operating income. The SEC’s financial-statements guide explains these differences. Compare like periods and distinguish recurring cash use from exceptional payments.
Build a budget around the milestone
Hypothetical example: a developer has US$90 million of available cash and uses US$5 million a month before financing. Simple division suggests 18 months. Its next trial result is expected in nine months.
Now assume there are US$20 million of additional trial costs and a US$10 million debt repayment before that result, neither included in the monthly figure. Nine months of ordinary spending uses US$45 million. After all three items, only US$15 million remains: US$90 million minus US$45 million, US$20 million and US$10 million.
If the result takes another three months and monthly spending continues unchanged, that remaining US$15 million is used up. This is a deliberately simplified illustration, with no new funding or other changes. It is not a company forecast or an estimate of typical trial costs.
The practical questions are which costs are included, when payments fall due, and what spending follows the milestone. Trial design and follow-up affect the development timetable; the FDA describes these stages.
Examine the funding assumptions
Read management’s liquidity discussion and risk disclosures alongside the latest financial statements. The SEC’s 10-K guide identifies these sections in an annual filing.
New funding changes the picture. Issuing shares can reduce a non-participating shareholder’s percentage ownership, as the SEC explains under dilution. Borrowing creates repayment obligations. A hoped-for financing should not be counted as money already available.
Which funding figure has reached the company?
A financing headline can describe several different amounts. Before adding one to a cash-runway estimate, check who receives the money and what conditions apply.
- Shares registered for resale. A document may cover an investor selling shares. Proceeds from those resales go to that investor. Check separately whether the company receives money from its own share sales.
- Funding available under an agreement. An “up to” amount is a ceiling. Further share sales may depend on specified conditions. Unused funding capacity is not a cash balance.
- Cash received by the company. Check the receipt date and whether the amount is before or after fees. Then account for spending and other cash movements since that date.
Hypothetical example: a company has an agreement allowing up to US$10 million of gross funding and reports US$3 million raised under that agreement, also before fees. Assuming the agreement terms are unchanged, US$7 million remains unused capacity. It is not money already received, and the US$3 million gross raising is not the company’s current cash balance.
The SEC’s prospectus guide explains the use-of-proceeds and risk sections. The financial-statements guide helps distinguish cash balances from movements. An Acurx prospectus dated 17 September 2026 illustrates separate resale proceeds and conditional company funding.
Our analytical takeaway is to test the assumptions behind a runway statement, including delays and spending after the milestone. A headline date cannot establish that the whole development plan is funded.
Educational information only. It does not take account of your objectives, financial situation or needs.
Sources and further reading
Sources checked 19 September 2026. Examples marked hypothetical illustrate concepts only.
Funding explanation added . Its additional sources were checked on 28 September 2026; the dated prospectus is an example, not a statement of current cash.